Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Antimitochindrial and antinuclear antibodies in primary biliary cholangitis
Dana Saipiyeva, Manarbek Askarov, Turlybek Tuganbekov, Kulsara Rustemova, Vladimir Grigorevsky, Gulmira Dossatayeva, Nina Tostanovskaya


In this work we reviewed the key antimitochondrial and antinuclear antibodies in primary biliary cholangitis – an autoimmune cholestatic disorder with destruction of intralobular biliary ductules. Since the discovery of antibodies to PDC-E2 component of cholangiocyte mitochondrial membrane, more than 60 antimitochindrial and antinuclear antibodies against various cellular components of cholangiocytes have been described to date, which have primary diagnostic and clinical value in identifying the disease progression and prognosis.

Keywords: cholestasis, PDC-E2, antinuclear antibodies, cholangiocytes, autoimmune hepatic disorder

Corresponding Author: Dana Saipiyeva, PhD student, No2 Department of Surgical Diseases, Astana Medical University, Nur-Sultan, Republic of Kazakhstan. Tel.: +7 707 031 18 34. E-mail:



1. Jepsen PA,, Grønbæk LA, Vilstrup. Worldwide Incidence of Autoimmune Liver Disease. Digestive Diseases. 2015; 33: 2-12.

2. Zukowski TH, Jorgensen RA, Dickson ER, Lindor KD. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. Am J Gastroenterol. 1998; 93(6):958-61.

3. Wang L, Zhang FC, Zhang X. Therapeutic advances for primary biliary cholangitis: the old and the new. European Journal of Gastroenterology & Hepatology. 2016; 28(6):615-621.

4. Scheenstra R, Peeters PM, Verkade HJ, Gouw AS. Graft fibrosis after pediatric liver transplantation: ten years of follow-up. Hepatology. 2009; 49:880-886.

5. Yamagiwa S, Kamimura H, Takamura M, Aoyagi Y. Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol. 2014; 20(10): 2606-2612.

6. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us. World Journal of Gastroenterology. 2010; 16(29):3616-3629.

7. Tanaka A, Nezu S, Uegaki S, Mikami M, Okuyama S, Kawamura N et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci. 2007; 1107:259-270.

8. Siekevitz P. Powerhouse of the cell. Scientific American. 197(1):131-140.

9. Andersson SG, Karlberg O, Canbäck B, Kurland CG. On the origin of mitochondria: a genomics perspective. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 358 (1429): 165-177; 177-179.

10. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death and Differentiation. 2006; 13(8):1396-402. doi:10.1038/sj.cdd.4401963. PMID 16710362.

11. Berg CP, Stein GM, Klein R, Pascu M, Berg T, Kammer W,et al. Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver Int. 2006;  26:846-855.

12. Nishio A1, Coppel R, Ishibashi H, Gershwin ME. The pyruvate dehydrogenase complex as a target autoantigen in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14(4):535-47.

13. Muratori L, Granito A, Muratori P, Pappas G, Bianchi F. Antimitochondrial Antibodies and OtherAntibodies in Primary Biliary Cirrhosis: Diagnostic and Prognostic Value. Clin Liver Dis. 2008; 12:261-276.

14. Preuss B, Berg C, Altenberend F, Gregor M, Stevanovic S, Klein R. Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance. Clin Exp Immunol. 2007; 150:312-321.

15. Mutimer DJ, Fussey SP, Yeaman SJ, et al. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology. 1989; 10:403-7.

16. Zhang FK, Jia JD, Wang BE. Clinical evaluation of serum antimitochondrial antibody-negative primary biliary cirrhosis. Hepatobiliary Pancreat Dis Int. 2004; 3:288-291.

17. Berg CP, Stein GM, Keppeler H, Gregor M, Wesselborg S, Lauber K. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis. 2008; 13:63-75.

18. Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008; 12:323-331; viii-ix.

19. Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int. 2008; 28:233-239.

20. Fusconi M, Cassani F, Govoni M, et al. Anti-nuclear antibodies of primary biliary cirrhosis recognize 78-92-kD and 96-100-kD proteins of nuclear bodies. Clin Exp Immunol. 1991; 83:291-7.

21. Wichmann I, Montes-Cano MA, Respaldiza N, Alvarez A, Walter K, Franco E, et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol. 2003; 38:996-999.

22. Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. 1997; 26:1123-30.

23. Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol. 1995; 42:257-68.

24. Szostecki C, Guldner HH, Will H. Autoantibodies against 'nuclear dots' in primary biliary cirrhosis. Semin Liver Dis. 1997; 17:71-8.

25. Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol. 2002; 127(1): 172-175.

26. Granito A., Wei-Hong Y., Muratori L., Lim M, Nakajima A., Ferri S.,et al. PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. The American Journal of Gastroenterology. 2010; 105:125-131.

27. Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun. 2006; 26:138-145.

28. Nakamura M, Komori A, Ito M, Kondo H, Aiba Y, Migita K, et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res. 2007; 37(3): S412-S419.

29. Bauer A1, Habior A2. Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis. Ann Lab Med. 2019; 39(3):291-298.

30. Dittmer, Travis A; Misteli, Tom. The lamin protein family. Genome Biology. 2011; 12(5):222.

31. Gruenbaum Y, Wilson K; Harel A; Goldberg M; Cohen M. Review: Nuclear Lamins-Structural Proteins with Fundamental Functions. Journal of Structural Biology. 2000; 129(2):313-323.

32. Alberts B, Bray D., Hopkin K., Johnson A., Lewis J., Raff M., et al. Essential Cell Biology. New York: Garland Science. 2014; 4.

33. Cheeseman I. The Kinetochore. Cold Spring Harb Perspect Biol. 2014; 6(7): a015826.

34. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007; 45:118-127.

35. Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med. 2008; 8:9-15.

36. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol. 2003; 98:431-437.

37. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001; 34:366-372.

38. Klein R, Pointner H, Zilly W, Glässner-Bittner B, Breuer N, Garbe W, et al. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: a prospective study on 200 patients followed for 10 years. Liver. 1997; 17(3):119-128.

39. Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol. 2002; 97(4):999-1002.

40. Dähnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem. 2009; 55(5):978-85.


Volume 2, Number 52 (2019)